Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns

AIDS. 2005 Dec 2;19(18):2167-9. doi: 10.1097/01.aids.0000194800.43799.94.

Abstract

The administration of single-dose nevirapine to women in labor and their infants can prevent HIV-1 mother-to-child transmission. We examined nevirapine resistance in infants who were HIV-1 infected despite single-dose nevirapine prophylaxis, including 18 Ugandan infants (HIVNET 012 trial, nine subtype A and nine subtype D) and 23 Malawian infants (NVAZ trial, all subtype C). Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0.016).

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Drug Resistance, Viral
  • Female
  • HIV Infections / prevention & control*
  • HIV Infections / transmission
  • HIV-1*
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control
  • Malawi
  • Nevirapine / administration & dosage*
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control*

Substances

  • Anti-HIV Agents
  • Nevirapine